Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Outcomes-based payment

- PMLiVE

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

Trial could begin by year end

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

Novartis day

Novartis cuts manufacturing jobs in Switzerland and UK

Cuts include closure of Grimsby site by 2020

- PMLiVE

NHS wins legal fight with pharma over off-label Avastin

Industry criticises judgement - fearful of 'undermining regulation' as well as big earning products

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

- PMLiVE

Health secretary’s ‘rip off’ remarks anger UK pharma

Row with Vertex has tainted government-industry relations

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links